Can erythropoietin therapy improve survival?
Anemia is a significant problem for cancer patients, especially those receiving chemotherapy. Preventing or treating anemia in these patients has clear cut quality of life improvements for the patients AND […]
A restrictive use of both autologous donation and recombinant human erythropoietin is an efficient policy for primary total hip or knee arthroplasty.
Finally a paper which tries to tell us when not to use these expensive modalities. Predonation and erythropoetin are essential tools in the reduction of allogeneic transfusion but their precise […]
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
This study by Henke et al. is certainly provocative. It reports a poor disease free and overall survival in head and neck cancer patients receiving locoregional radiation therapy. What might […]
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
This positive study demonstrated that epoetin patients did better than no epoetin control patients in a relapsed lymphoma, autologous stem cell transplant setting. Epoetin has been shown not to be […]
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early […]